A Minority of Patients With High-Risk Polycythemia Vera Receive Cytoreductive Medication

Despite European LeukemiaNet and National Comprehensive Cancer Network guideline recommendations that patients with high-risk polycythemia vera (PV) should receive cytoreductive therapy along with phlebotomy and low-dose aspirin, a retrospective study found that only 42% of patients with high-risk PV received the recommended cytoreductive therapy.

Videos

Perspectives on the Collaborative Management of Myeloproliferative Neoplasms

Advertisement

In The News

Oncology Nurse Advisor

Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis

American Journal of Managed Care

New Guideline Released on Managing Complications in Polycythemia Vera

Oncology Nurse Advisor

Case Study: Myelofibrosis Diagnosis and Early Intervention

Cure

Encouraging Preliminary Results in Myelofibrosis Trial Lead to Enhancements in Phase 2

HemOnc Today

Ruxolitinib-Azacitidine Combination Shows ‘Synergistic Efficacy’ for Myelofibrosis

View all >

In The Literature

Blood (ASH Abstract)

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients with Myelofibrosis

Blood (ASH Abstract)

Independent Association of Male Sex With Presentation and Clinical Outcomes in Myeloproliferative Neoplasms

Blood (ASH Abstract)

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib With Best Available Therapy in Hydroxyurea-Resistant/Intolerant Patients with Polycythemia Vera

American Journal of Hematology

Myeloproliferative Neoplasms in the Young: Mayo Clinic Experience With 361 Patients Age 40 Years or Younger

European Journal of Haematology

Frequency and Etiology of Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms

View all >